BioMarin Pharmaceutical Inc. BMRN R3KPHARMA
Company Overview
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
Why Investors Should Care
Net profit has compounded at 15.3% per year over the last five years.
Revenue has grown at a 15.1% CAGR over the past five years.
Operating margin of 21.2% supports profitability.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $3.22B (+12.9% YoY); net profit $348.90M.
- Trailing 12 Months Year-on-year growth — revenue +19.9%, earnings -81.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 15.1%, profit CAGR 15.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 15.06% |
| 1 Year: | 19.90% |
Compounded Profit Growth
| 5 Years: | 15.34% |
| 1 Year: | -81.30% |
Stock Price Performance
| 1 Year: | +10.86% |
| 6 Months: | +6.16% |
| 3 Months: | +14.29% |
| 1 Month: | +1.29% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)48.84 · Neutral
P/E of 174.68 is above the sector median of 24.83 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 15.1% over 5 years.
- Profit CAGR of 15.3% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 174.7.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BMRN BioMarin Pharmaceutical Inc. R3KPHARMA | 64.63 | 174.68 | $12.51B | 0.00% | 5.99% | 1.18% | 15.06% | 15.34% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 317.45M | 334.15M | 373.45M | 372.85M | 391.71M | 400.75M | 387.76M | 461.10M | 502.07M | 429.49M | 476.78M | 486.03M | 501.69M | 408.74M | 519.36M | 533.80M | 505.34M | 596.41M | 595.27M | 581.33M | 648.83M | 712.03M | 745.74M | - | 745.14M | 825.41M | 776.13M | 874.57M | 766.21M | 989.71M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 151.56M | 150.09M | 140.09M | 275.71M | 195.00M | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 593.59M | 675.32M | 636.05M | 598.86M | 571.21M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 369.68M | 398.45M | 682.73M | 643.46M | 441.58M | - |
| Operating Income | -26.46M | -18.88M | 11.20M | -65.86M | -64.29M | -81.87M | -80.92M | -572.81M | -60.09M | -20.21M | -38.81M | -13.73M | -44.37M | -25.26M | -15.74M | -53.95M | -41.35M | 4.01M | 104.96M | -40.95M | -55.94M | 25.09M | 11.67M | -53.22M | 137.33M | 39.15M | -2.42M | 62.40M | 65.57M | 30.52M | 88.46M | 120.45M | 113.89M | - | 223.91M | 276.87M | -46.68M | -44.60M | 129.63M | 110.92M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 263.02M | 319.11M | -5.26M | -3.94M | 172.57M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.86M | 2.68M | 2.58M | 2.78M | 14.96M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 238.09M | 297.87M | -26.32M | -27.15M | 141.20M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 52.40M | 57.34M | 4.42M | 19.42M | 35.68M | - |
| Net Income | -38.12M | -33.50M | 7.45M | -67.50M | -81.99M | -90.93M | -83.05M | -419.01M | -37.42M | -16.29M | -36.83M | -12.53M | -44.15M | -16.79M | -12.62M | -56.47M | -37.44M | 55.04M | 81.38M | -29.18M | 784.80M | 17.37M | 12.94M | -36.49M | 120.80M | 27.66M | -6.65M | 50.85M | 56.04M | 40.38M | 88.66M | 107.17M | 106.08M | - | 185.69M | 240.53M | -30.74M | -46.57M | 105.53M | 44.76M |
| Diluted EPS | -0.27 | -0.23 | 0.05 | -0.43 | -0.51 | -0.60 | - | - | -0.22 | -0.09 | - | -0.07 | -0.26 | - | -0.07 | -0.32 | -0.21 | 0.30 | 0.44 | -0.16 | 4.01 | 0.09 | 0.07 | -0.20 | 0.63 | 0.15 | -0.04 | 0.27 | 0.29 | 0.21 | 0.46 | 0.55 | 0.55 | - | 0.95 | 1.23 | -0.16 | -0.24 | 0.54 | 0.23 |
| R&D Expense | 86.17M | 107.70M | 125.69M | 142.07M | 157.90M | 158.71M | 158.79M | 167.04M | 160.83M | 145.00M | 143.04M | 154.10M | 183.95M | 175.58M | 161.41M | 183.59M | 185.64M | 172.96M | 142.26M | 182.14M | 147.05M | 148.72M | 161.11M | 157.87M | 160.84M | 158.19M | 157.83M | 171.85M | 177.36M | 191.31M | 204.99M | 183.79M | 184.90M | - | 158.73M | 161.31M | 409.48M | - | 178.80M | 206.95M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 296.49M | 324.66M | 376.27M | 441.36M | 500.72M | 548.49M | 749.28M | 889.89M | 1.12B | 1.31B | 1.49B | 1.70B | 1.86B | 1.85B | 2.10B | 2.42B | 2.85B | 3.22B |
| Operating Income | 39.76M | 16.43M | 544.00K | -33.89M | -110.22M | -156.01M | -92.89M | -110.70M | -803.43M | -14.70M | -123.52M | -100.46M | -43.44M | -82.34M | 160.97M | 185.77M | 484.21M | 409.48M |
| Net Income | 30.83M | -488.00K | 205.82M | -53.84M | -114.35M | -176.35M | -133.97M | -171.80M | -630.21M | -117.04M | -77.21M | -23.85M | 854.03M | -64.08M | 141.56M | 167.65M | 426.86M | 348.90M |
| Diluted EPS | 0.29 | 0.00 | 1.73 | -0.48 | -0.95 | - | -0.92 | -1.07 | -3.81 | -0.67 | -0.44 | -0.13 | 4.50 | -0.35 | 0.75 | 0.87 | 2.21 | 1.80 |
| R&D Expense | 93.29M | 115.12M | 147.31M | 214.37M | 302.22M | 354.78M | 461.54M | 634.81M | 661.90M | 610.75M | 696.33M | 715.01M | 628.12M | 628.79M | 649.61M | 746.77M | 747.18M | 921.93M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 917.16M | 1.26B | 1.31B | 1.57B | 2.24B | 2.48B | 3.73B | 4.02B | 4.63B | 4.43B | 4.69B | 5.85B | 6.00B | 6.38B | 6.84B | 6.99B | 7.59B |
| Total Equity | 187.73M | 276.68M | 322.19M | 717.26M | 773.05M | 1.02B | 1.34B | 1.53B | 2.40B | 2.77B | 2.81B | 2.97B | 3.12B | 4.10B | 4.27B | 4.60B | 4.95B | 5.66B | 6.09B |
| Cash & Equivalents | 228.34M | 222.90M | 167.17M | 88.08M | 46.27M | 180.53M | 568.78M | 875.49M | 397.04M | 408.33M | 598.03M | 493.98M | 437.45M | 649.16M | 587.28M | 724.53M | 755.13M | 942.84M | 1.31B |
| Total Liabilities | - | - | 594.98M | 545.37M | 532.66M | 552.58M | 903.02M | 947.49M | 1.33B | 1.26B | 1.82B | 1.46B | 1.57B | 1.74B | 1.74B | 1.77B | 1.89B | 1.33B | 1.51B |
| Current Liabilities | - | - | 78.15M | 83.84M | 94.12M | 170.43M | 183.27M | 235.74M | 445.46M | 439.31M | 816.52M | 523.24M | 932.50M | 492.55M | 546.50M | 588.88M | 1.18B | 606.99M | 759.03M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -9.18M | 87.73M | 18.75M | 18.41M | 17.61M | -59.63M | - | - | -227.84M | -8.76M | 20.21M | 48.26M | 85.36M | 304.54M | 175.90M | 159.26M | 572.84M | 827.99M |
| Investing Cash Flow | -19.08M | -79.67M | -101.34M | -89.56M | -195.65M | -298.78M | - | - | -484.05M | -305.46M | 264.35M | -31.03M | -53.62M | -366.31M | -20.03M | -111.24M | 136.49M | -414.24M |
| Financing Cash Flow | 22.81M | -63.79M | 3.50M | 29.34M | 312.29M | 746.67M | - | - | 727.11M | 507.14M | -388.01M | -74.67M | 181.12M | -48.00K | -18.65M | -18.73M | -526.45M | -42.39M |
| Capital Expenditure | -56.37M | -89.80M | -49.46M | -73.22M | -44.57M | -65.19M | -117.06M | -227.65M | -148.38M | -199.22M | -144.62M | -145.03M | -114.31M | -95.58M | -120.96M | -96.69M | -85.42M | -103.04M |
| Free Cash Flow | -65.54M | -2.07M | -30.71M | -54.80M | -26.96M | -124.83M | - | - | -376.22M | -207.98M | -124.41M | -96.76M | -28.95M | 208.96M | 54.94M | 62.57M | 487.42M | 724.96M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 50.00M | 0 | 0 | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 13.4% | 5.1% | 0.1% | -7.7% | -22.0% | -28.4% | -12.4% | -12.4% | -71.9% | -1.1% | -8.3% | -5.9% | -2.3% | -4.5% | 7.7% | 7.7% | 17.0% | 12.7% |
| Net Margin % | 10.4% | -0.2% | 54.7% | -12.2% | -22.8% | -32.2% | -17.9% | -19.3% | -56.4% | -8.9% | -5.2% | -1.4% | 45.9% | -3.5% | 6.8% | 6.9% | 15.0% | 10.8% |
| ROE % | 11.1% | -0.2% | 28.7% | -7.0% | -11.3% | -13.2% | -8.8% | -7.2% | -22.8% | -4.2% | -2.6% | -0.8% | 20.8% | -1.5% | 3.1% | 3.4% | 7.5% | 5.7% |
| ROCE % | - | 2.0% | 0.0% | -2.8% | -7.9% | -7.6% | -4.1% | -3.4% | -22.4% | -0.4% | -3.2% | -2.7% | -0.8% | -1.5% | 2.8% | 3.3% | 7.6% | 6.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 10.56% | 20.45M | $1.31B |
| 2 | Dodge & Cox Inc. | 7.67% | 14.84M | $949.18M |
| 3 | Primecap Management Company | 7.33% | 14.19M | $907.32M |
| 4 | Vanguard Capital Management LLC | 4.52% | 8.74M | $559.07M |
| 5 | Vanguard Portfolio Management LLC | 4.47% | 8.65M | $553.00M |
| 6 | NORGES BANK | 4.24% | 8.21M | $524.82M |
| 7 | State Street Corporation | 4.03% | 7.80M | $498.79M |
| 8 | Viking Global Investors, L.P. | 3.93% | 7.62M | $487.00M |
| 9 | Vestal Point Capital, LP | 3.11% | 6.03M | $385.24M |
| 10 | AQR Capital Management, LLC | 2.94% | 5.70M | $364.43M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BMRN
3 Reasons to Avoid BMRN and 1 Stock to Buy Instead - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxQQXNXWDJ4ZDhGOWtwYWhlMG1MLVNLeFg3b3FLVEs5eldHMEtuaHZwdmo1MEk4X0pBQWwyaUl5M0ZwOEcxdFRPekZaZUpOaTN3cjUzYmVvSDVORVZTamMxUk9kQ1U1WWJxeC1pVlYyY3NXVzYyaXVEV1lsWnJza3BuU2lpWkVnampPdVJId2…
Royalty Deal Could Be A Big Development For BioMarin Stock (BMRN) - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxPWTN6XzVSMFpGSWZxZ2dmSExpTU43TEFoN09xaEtlb2RTOTl1ZXQzSFJrdUxhaXROR25pMGdIc0gwMlQxUGtReGJ2MVFXd29heFRidERpc1k2M1VZXzFiOWRydkxnU25XOG5TSDVXQ1Z0Z3Z1MEJ4Nnhjel9zLTlJX2VhN05QQ1JuWVhMNl…
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: 37% Upside Potential Amid Robust Revenue Growth - directorstalkinterviews.com
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxPVkZyODBkNTFCTl9WYXE1MTNzb2RiQ0RiS3M3S2c4dThaWEk3UjRIY08tUDlCNXB3cG83SDdKNlpHRzdkWXNpMjRsclNlcG9DQmV4cE02OXU0UVF1cjFpZ3ZOY3RXWnFMSURNWUFsank3WnBVbUlQU3lINEJyYTBRWVJIMzB0OGJZa1BOOU…
BioMarin Reports Second Quarter 2026 Financial and Operating Results - PR Newswire
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQZDI4aDdqR1dCZ2RyaHJEcW1lWi1OTXIyUDFRZHdhUVRWMjltRzFNX0g5VDhWSy1HSTRnS1BJaE5ULU15NTJCbGRsa2s3bGZGRFlXY0VycG1tdlVzZU8xYk51cGtTc3htRGxzZGNBYUdQR19GdE5qdWxlMWJTZHVnYjlTZVMwRWtMUEljc0…
ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxOc081N2tqLUVIOWdySXJKLVE2SlV3TlVfNzF4d0t1ajAyaG96d1U3UVhvakVzcWZDVEdlRGdEZnJWUUNzRWlxOTcxZy1qb0pLazFBeDI1X1gyZ0x5M0RicXBrV0s1alBYSTBsR2lFclZVUTlIOHFXVmxQa19lLURydFNpdFg2dlQ5dWVhWX…
BioMarin (NASDAQ: BMRN) legal chief unloads 17,557 shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQUS0yaGs5V3ljRzd3ck1jTnpIX0lmNjIwY3R5WVNPSHRFbTdRYjZ2VEc4T3Z5SkVwRmxvR2xIM2FJb1hfa3lYZGVRZTRJTm1jbk5RWFJpbndyUVJIZG1lcjdSNE0ydGNyQnI5OXJkalMxN3N5MC1acUk4ZzQwZnd0TG5ib1hkQmVTZHRzYm…
BMRN — Frequently Asked Questions
What is the current share price of BioMarin Pharmaceutical Inc. (BMRN)?
As of 2026-09-19 21:16 PDT, BioMarin Pharmaceutical Inc. (BMRN) trades at $64.63 on NasdaqGS. Its 52-week range is $49.67 to $70.24.
What is the market capitalisation of BMRN?
BioMarin Pharmaceutical Inc. (BMRN) has a market capitalisation of $12.51B on NasdaqGS.
What is the P/E ratio of BMRN?
BMRN trades at a trailing price-to-earnings (P/E) ratio of 174.68. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.97.
What is the return on equity (ROE) of BMRN?
BMRN has a return on equity (ROE) of 1.18%. Its return on capital employed (ROCE) is 5.99%.
Is BMRN a good stock to buy?
This page provides a data-driven analysis of BioMarin Pharmaceutical Inc. (BMRN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.